On August 14, Twist Bioscience Corp declined 5.36% in regular trading, trading at $119.06/share, with turnover of $57.72 million.

The pullback comes amid profit-taking pressure following a roughly 295% year-to-date surge driven by the AI-enabled drug discovery narrative. The company reported fiscal Q3 results on August 3 showing EPS of -$0.56, missing the consensus estimate of -$0.50, though revenue of $118.4 million beat expectations of $114.5 million. Q4 revenue guidance of $123M-$124M also exceeded the FactSet estimate of $117.4M. Despite strong revenue momentum and the approaching adjusted EBITDA breakeven milestone, market commentators have flagged the need for maintaining safety margins when chasing elevated valuations, warning investors to prioritize cash flow delivery over narrative momentum in high-volatility names.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)